Edition:
India

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

21.54USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$21.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
111,555
52-wk High
$25.74
52-wk Low
$13.93

Latest Key Developments (Source: Significant Developments)

Intra-Cellular Therapies Reports Q2 Results
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Intra-Cellular Therapies Inc ::INTRA-CELLULAR THERAPIES PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.68.Q2 EARNINGS PER SHARE VIEW $-0.76 -- THOMSON REUTERS I/B/E/S.INTRA-CELLULAR THERAPIES - EXPECTS CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES OF $403.8 MILLION AS OF JUNE 30 TO BE USED FOR LUMATEPERONE PROGRAM.  Full Article

Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Intra-cellular Therapies Inc ::Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia.Intra-Cellular Therapies Inc - ‍food and drug administration granted fast track designation for lumateperone for treatment of Schizophrenia​.  Full Article

Intra-Cellular Therapies Q3 loss per share $0.53
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.53.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cash, cash equivalents, investment securities totaled $328.1 million at September 30, 2017, versus $384.1 million at December 31, 2016​.Expect to complete patient enrollment in our bipolar studies in 2018​.  Full Article

BRIEF-Intra-Cellular Therapies Reports Q1 Loss Per Share $0.65

* INTRA-CELLULAR THERAPIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE